All In MedTech

Device Trial Radar · NCT07932847

Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory Failure

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Randomized Substudy in a Conventional Hospital Ward

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Aether Tech S.L.Not on our public-company list
Sponsor type
Industry
Collaborators
Hospital Universitario Fundación Jiménez Díaz
First posted
Nov 12, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient. Adults admitted to the pulmonology ward of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) with acute respiratory failure are randomly assigned to receive oxygen titrated automatically by EMILY.AI or oxygen managed as usual by the nursing team, from randomization until hospital discharge. All participants wear the device; in the usual-care group it only records data. The study compares the time patients stay within their target saturation range, episodes of low and high oxygen, nursing workload, oxygen use, length of stay and patient experience. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Conditions

  • Acute Respiratory Failure
  • Acute-on-chronic Respiratory Failure
  • COPD Exacerbation
  • Pneumonia
  • Interstitial Lung Diseases

Interventions

  • EMILY.AI closed-loop oxygen titrationDevice

    Investigational smart oxygen valve with rule-based algorithm that adjusts oxygen flow to keep SpO2 within a target range.

  • Manual oxygen titrationOther

    Usual care: oxygen flow set and adjusted by the ward nursing team according to standard practice. The EMILY.AI device stays connected in fixed mode, recording signals but not controlling delivery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EFFICACY - EVALUATION OF THE RATE THE DEVICE MAINTAINS BLOOD OXYGEN SATURATION LEVELSTime frame: From randomization to hospital discharge, up to 30 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.